The US Food and Drug Administration's Approval of Adjuvant Sunitinib for Renal Cell Cancer: A Case of Regulatory Capture?

JAMA Oncol. 2018 May 1;4(5):623-624. doi: 10.1001/jamaoncol.2017.5697.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Renal Cell / diagnosis
  • Carcinoma, Renal Cell / drug therapy*
  • Chemotherapy, Adjuvant
  • Drug Approval*
  • Humans
  • Kidney Neoplasms / diagnosis
  • Kidney Neoplasms / drug therapy*
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Sunitinib / administration & dosage
  • Sunitinib / adverse effects
  • Sunitinib / therapeutic use*
  • Treatment Outcome
  • United States
  • United States Food and Drug Administration

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Sunitinib